ARO-INHBE
PreclinicalSmall molecule
Arrowhead PharmaceuticalsARO-INHBE is one of 46 small molecule programs targeting Obesity. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
176 competitors in Obesity
#DrugCompanyPhaseTrials
1Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Maridebart Cafraglutide
AmgenPhase 3
Enavogliflozin
Daewoong Pharmaceutical Co. LTD.Phase 3
HRS9531
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Cagrisema
Novo NordiskPhase 3
Eloralintide
Eli LillyPhase 3
Naltrexone-Bupropion Combination
CCurrax Pharmaceuticals
Phase 3
Belantamab Mafodotin-Blmf
Novo NordiskPhase 3
Semaglutide or Tirzepatide
NNational and Kapodistrian University of Athens
Phase 3
Actemra
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ARO-INHBE. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company